A Phase 3 interventional study of ADX-2191 (intravitreal methotrexate 0.8%) and Standard surgical care procedure in Proliferative Vitreoretinopathy, sponsored by Aldeyra Therapeutics, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Vitreoretinopathy, Proliferative with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Vitreoretinopathy, Proliferative · United States.
Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 3, and was the 7th registered.
43 studies on the registry are indexed under Vitreoretinopathy, Proliferative; 11 are open to participants now.
Browse Vitreoretinopathy, Proliferative studies →2 of the 12 studies in Vitreoretinopathy, Proliferative with a site in United States are open now. Recruiting first, the newest first:
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+ · Healthy volunteers
Cincinnati Eye Institute, Southwest Ohio · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Vitreoretinopathy, Proliferative studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 2 · Phase 4 2
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 64 across 30 interventional studies indexed under Vitreoretinopathy, Proliferative.
Median enrollment 69 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Aldeyra Therapeutics, Inc. has 1 study filed under Vitreoretinopathy, Proliferative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
Drug: ADX-2191 (intravitreal methotrexate 0.8%)
Standard procedure performed.
Other: Standard surgical care procedure
ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Standard surgical care performed upon completion of pars plana vitrectomy
Recurrent Retinal Detachment Compared to Historical Rates
Percentage of subjects with recurrent retinal detachments requiring reoperation compared to historical rates
Time frame: Efficacy assessment period (Week 1 to Week 24)
Number of Subjects With Recurrent Retinal Detachment
Number of subjects with recurrent retinal detachment due to proliferative vitreoretinopathy
Time frame: Efficacy assessment period (Week 1 to Week 24)
Best-corrected Visual Acuity
Change from baseline of best-corrected visual acuity using an early treatment diabetic retinopathy study (ETDRS) chart. The ETDRS chart contains seventy letters and the visual acuity letter score is equal to the total number of letters read correctly (0 = worst outcome, 70 = best outcome).
Time frame: Efficacy assessment period (Week 1 to Week 24)
Macular Epiretinal Membrane
Number of subjects with macular epiretinal membrane assessed by spectral domain optical coherence tomography for study eye
Time frame: Week 24
Intraocular Pressure Less Than 5 mmHg for Study Eye
Number of subjects with intraocular pressure less than 5 mmHg for study eye
Time frame: Week 24
Central Macular Subfield Thickness
Number of subjects with central macular subfield thickness assessed by spectral domain optical coherence tomography for study eye
Time frame: Week 24
| Milestone | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Started | 68 | 38 |
| Completed | 52 | 32 |
| Not completed | 16 | 6 |
Percentage of subjects with recurrent retinal detachments requiring reoperation compared to historical rates
| percentage of subjects | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Recurrent Retinal Detachment Compared to Historical Rates | 18.8 | 20.6 |
Number of subjects with recurrent retinal detachment due to proliferative vitreoretinopathy
| Participants | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Number of Subjects With Recurrent Retinal Detachment | 12 | 7 |
Change from baseline of best-corrected visual acuity using an early treatment diabetic retinopathy study (ETDRS) chart. The ETDRS chart contains seventy letters and the visual acuity letter score is equal to the total number of letters read correctly (0 = worst outcome, 70 = best outcome).
| correct letters | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Best-corrected Visual Acuity | 16.9 ± 23.2 | 22.5 ± 27.4 |
Number of subjects with macular epiretinal membrane assessed by spectral domain optical coherence tomography for study eye
| Participants | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Macular Epiretinal Membrane | 18 | 12 |
Number of subjects with intraocular pressure less than 5 mmHg for study eye
| Participants | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Intraocular Pressure Less Than 5 mmHg for Study Eye | 2 | 4 |
Number of subjects with central macular subfield thickness assessed by spectral domain optical coherence tomography for study eye
| microns | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Central Macular Subfield Thickness | 384.4 ± 185.24 | 473.7 ± 228.95 |
Collected over The safety assessment period was up to twenty-four weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-2191 | 0/68 (0%) | 0/68 (0%) | 39/68 (57.4%) |
| Standard Surgical Care | 0/38 (0%) | 1/38 (2.6%) | 24/38 (63.2%) |
| Event | ADX-2191 | Standard Surgical Care |
|---|---|---|
| DizzinessNervous system disorders | 0/68 | 1/38 |
| Event | ADX-2191 | Standard Surgical Care |
|---|---|---|
| Eye painEye disorders | 9/68 | 9/38 |
| Intraocular pressure increasedInvestigations | 2/68 | 8/38 |
| Punctate keratitisEye disorders | 11/68 | 1/38 |
| Macular fibrosisEye disorders | 4/68 | 6/38 |
| Cystoid macular oedemaEye disorders | 5/68 | 5/38 |
| Post procedural inflammationInjury, poisoning and procedural complications | 1/68 | 5/38 |
| Corneal oedemaEye disorders | 4/68 | 4/38 |
| Corneal epithelium defectEye disorders | 2/68 | 4/38 |
| Anterior chamber cellEye disorders | 1/68 | 4/38 |
| KeratitisEye disorders | 6/68 | 2/38 |
Safety population
| Age, Categorical(Participants) | ADX-2191 | Standard Surgical Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 50 | 23 | 73 |
| >=65 years | 18 | 15 | 33 |
| Sex: Female, Male(Participants) | ADX-2191 | Standard Surgical Care | Total |
|---|---|---|---|
| Female | 51 | 24 | 75 |
| Male | 17 | 14 | 31 |
| Ethnicity (NIH/OMB)(Participants) | ADX-2191 | Standard Surgical Care | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 10 |
| Not Hispanic or Latino | 60 | 35 | 95 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | ADX-2191 | Standard Surgical Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 8 |
| White | 58 | 32 | 90 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(participants) | ADX-2191 | Standard Surgical Care | Total |
|---|---|---|---|
| United States | 68 | 38 | 106 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Jun 2022, 30 months.
Results were first posted in Jul 2025, 3 years after primary completion. A results delay was requested in May 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate
Vitreoretinopathy, Proliferative →